Dr. Ryotaro Nakamura, MD

Dr. Nakamura practices at City of Hope Comprehensive Cancer Center - Duarte in Duarte, California.

Dr. Nakamura's NPI, 1629174552, was assigned on September 16, 2006. Dr. Nakamura graduated from Other in 1991. Dr. Nakamura's California license number on file is A78860.

Dr. Nakamura's primary practice is City of Hope Comprehensive Cancer Center - Duarte, at 1500 Duarte Rd, Duarte, CA 91010 in Los Angeles County. The practice phone is (800) 826-4673.

Dr. Nakamura's primary practice is City of Hope Comprehensive Cancer Center - Duarte in Duarte, California. Dr. Nakamura is also affiliated with Providence St. Jude Medical Center. The medical group on file is City of Hope. Dmand AI also links Dr. Nakamura to 1 more other site, named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Nakamura practices, 2 sites in all. Vendor and product names are available with a free account.

Internal medicine is Dr. Nakamura's primary specialty in the NPI Registry, under taxonomy code 207RH0000X. The record also lists hematology. Dr. Nakamura is board certified in hematology by the American Board of Internal Medicine. Dmand AI has Dr. Nakamura's licenses on file in 2 states: California and Maryland.

Dmand AI lists anemia, chronic anemia, chronic leukemia, deep vein thrombosis (DVT), lymphoma, multiple myeloma and neutropenia among the conditions Dr. Nakamura treats.

CMS data shows 1,005 Medicare services from Dr. Nakamura across 8 procedure codes in 2024, for 160 Medicare patients. Medicare paid $61,001 for them.

CMS counts 160 Medicare patients who saw Dr. Nakamura in 2024. The largest group is 65 to 74, with 70 patients. 74% of them have high blood pressure, and 70% have high cholesterol. 28% are also on Medicaid. Their average risk score is 3.74, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Nakamura's median patient age at 67, with 50% women.

In 2024, Dr. Nakamura wrote 426 Medicare Part D claims for 58 patients. 74% of them were for generic drugs. CMS names the drug for 221 of them, across 9 drugs with 11 or more claims each, at $744,570 in total drug cost. In 2023, CMS named 175 claims across 7 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 93 out of 100 for Dr. Nakamura for performance year 2024, reported as part of a group. Dr. Nakamura accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Nakamura as offering telehealth.

Dmand AI links 294 papers to Dr. Nakamura, published from 2002 to 2025. 2020 was the busiest year, with 26. The most frequent topics are Hematopoietic Stem Cell Transplantation, Graft vs Host Disease and Transplantation, Homologous. Dr. Nakamura has published most often in Biol Blood Marrow Transplant. Dr. Nakamura's most frequent co-authors are Stephen J. Forman, MD, Haris Ali, MD and Anthony S. Stein, MD.

Dmand AI links Dr. Nakamura to 13 clinical trials, 5 of them phase 1 studies. 5 are still active or recruiting. Conditions studied include Leukemia, Myeloid, Accelerated Phase, Leukemia, Myeloid, Chronic-Phase and Lymphoma, B-Cell. City of Hope Medical Center sponsors the most, 8.

CMS Open Payments shows 69 general payments to Dr. Nakamura from 20 drug and device companies from 2016 to 2025. Consulting fees make up the largest share, 76% of the total. Sanofi and Genzyme US Companies paid the most, $19,180. It also lists 3 research payments totaling $2,210 from 2024 to 2025.

Dr. Nakamura graduated from Other in 1991. Dr. Nakamura is a member of ASH.

Dr. Nakamura is in network with 7 carriers, including Aetna, Elevance and Blue Cross Blue Shield of Michigan. Medicare plans come from the most carriers, 7. Check the plan with the practice before a visit.